SCHEMBL2926489

SCHEMBL2926489

CC(=O)Oc1coc2cc(C(F)(F)F)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 2/20 0.54
CYP2C19 P33261 2/20 0.54
USP2 O75604 1/20 0.54
HPGD P15428 1/20 0.54
HSD17B10 Q99714 1/20 0.54
BACE1 P56817 1/20 0.47
PPARD Q03181 3/20 0.40
PPARA Q07869 2/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 1/20 0.39
POLB P06746 3/20 0.38
PPARG P37231 1/20 0.38
KIF11 P52732 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12099914 0.79 MAPT (0.51) KDM4EALDH1A1CYP2C19HPGDHSD17B10
SCHEMBL437186 0.79 KMT2A (0.51) KDM4EALDH1A1CYP2C19USP2HPGD
SCHEMBL5502413 0.79 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL15897821 0.78 ALDH1A1 (0.46) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL12164332 0.78 ABCB11 (0.48) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL31493875 0.78 ABCB11 (0.48) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL12687295 0.78 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL3921973 0.77 SMN1; SMN2 (0.53) KDM4EALDH1A1CYP2C19HPGDHSD17B10
SCHEMBL1714974 0.75 KDM4E (0.62) KDM4EALDH1A1CYP2C19USP2HPGD
SCHEMBL5761877 0.73 TSHR (0.50) KDM4EALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KDM4E 1568/4885ALDH1A1 1667/4885CYP2C19 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.